440 Collins Street
Melbourne, VIC 3000
1300 301 874
Industry: Drug Manufacturers—General
|Dr. Peter Laurence Molloy BSc, FAICD, MBA||Founder, Exec. Chairman & CEO||324.3k||N/A||1954|
|Dr. Stephen Francis Goodall MASc, MBA||Founder, COO & Exec. Director||250.43k||N/A||N/A|
|Mr. Kavi Bekarma B.Sc., C.A.||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Simon Tucker||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Robyn Branigan||Head of Marketing||N/A||N/A||N/A|
|Prof. Peter Friedland||Chief Medical Officer||N/A||N/A||N/A|
|Dr. Monique Baldwin||Head of Regulatory Affairs||N/A||N/A||N/A|
|Mr. Stephen Buckley||Company Sec.||N/A||N/A||N/A|
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Firebrick Pharma Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.